Cargando…
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
NEO-201 is a novel humanized IgG1 monoclonal antibody that was derived from an immunogenic preparation of tumor-associated antigens from pooled allogeneic colon tumor tissue extracts. It was found to react against a variety of cultured human carcinoma cell lines and was highly reactive against the m...
Autores principales: | Fantini, Massimo, David, Justin M., Saric, Olga, Dubeykovskiy, Alexander, Cui, Yongzhi, Mavroukakis, Sharon A., Bristol, Andrew, Annunziata, Christina M., Tsang, Kwong Y., Arlen, Philip M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758533/ https://www.ncbi.nlm.nih.gov/pubmed/29354121 http://dx.doi.org/10.3389/fimmu.2017.01899 |
Ejemplares similares
-
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
por: Tsang, Kwong Y., et al.
Publicado: (2022) -
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer
por: Zeligs, Kristen P., et al.
Publicado: (2020) -
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
por: Fantini, Massimo, et al.
Publicado: (2019) -
Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas
por: Tsang, Kwong yok, et al.
Publicado: (2022) -
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
por: Cole, Christopher B., et al.
Publicado: (2023)